Impact BioMedical, Inc. (IBO)vsRegeneron Pharmaceuticals Inc (REGN)
IBO
Impact BioMedical, Inc.
$0.46
+4.35%
HEALTHCARE · Cap: $52.83M
REGN
Regeneron Pharmaceuticals Inc
$793.74
+1.57%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 44384757% more annual revenue ($15.53B vs $35,000). IBO leads profitability with a 2260.0% profit margin vs 27.9%. IBO trades at a lower P/E of 0.6x. REGN earns a higher WallStSmart Score of 66/100 (B-).
IBO
Avoid32
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IBO.
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$793.74
$610.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 2260 of every $100 in revenue as profit
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -112.2% — below average capital efficiency
Revenue declined 57.1%
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : IBO
The strongest argument for IBO centers on P/E Ratio, Profit Margin. Profitability is solid with margins at 2260.0% and operating margin at -23400.0%.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : IBO
The primary concerns for IBO are EPS Growth, Market Cap, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
IBO profiles as a declining stock while REGN is a growth play — different risk/reward profiles.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (66/100 vs 32/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Utilizing advanced research methodologies, the firm aims to improve patient outcomes and overall quality of life. With a robust intellectual property portfolio and an emphasis on scientific rigor, Impact BioMedical is well-positioned for growth in the evolving healthcare market. Its extensive product pipeline and strategic collaborations offer attractive investment opportunities for institutional investors interested in the accelerating biopharmaceutical sector.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?